The merged product will bring the best of both worlds in a single web application, covering all journeys from identifying the likely causal signals to the prioritising factors relevant to target progression

This update will power our current target identification coverage, as well as the mechanistic interpretation and biological context

The update will include a refreshed post-GWAS analysis covering state-of-the-art data and methodologies, resulting on 2.5M GWAS and molQTL credible sets, colocalisation analysis and L2G predictions

From next spring, the Open Targets Platform will incorporate the best of Open Targets Genetics into an integrated drug discovery platform 🧵